Request Demo
Last update 20 Mar 2025
Teriparatide Acetata(Sawai Pharmaceutical)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms- |
Target |
Action agonists |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (17 Jun 2022), |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with Teriparatide Acetata(Sawai Pharmaceutical)NCT03133195
A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With Proximal Femoral Nail Antirotation (PFNA)
JPRN-UMIN000023344
The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis - The efficacy of teriparatide for the bone strength of patients suffered proximal femoral fracture, evaluated by computed tomographic finite element analysis
JPRN-UMIN000022598
Study on inhibitory effect of teriparatide in knee osteoarthritis - Inhibitory effect of teriparatide in knee osteoarthritis
100 Clinical Results associated with Teriparatide Acetata(Sawai Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Teriparatide Acetata(Sawai Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Teriparatide Acetata(Sawai Pharmaceutical)
Login to view more data
100 Deals associated with Teriparatide Acetata(Sawai Pharmaceutical)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Osteoporosis | Japan | 17 Jun 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 415 | qfxroxflcs(xhudunxihu) = avdsdhsycy yqridyciui (uxhoyvrmzh ) | Positive | 04 May 2023 | |||
Placebo | qfxroxflcs(xhudunxihu) = mzolznjktl yqridyciui (uxhoyvrmzh ) | ||||||
Not Applicable | 200 | vgdsahimdy(ndvmgzgutf) = Wedge type vobpdckizi (bbhexptyss ) | Positive | 04 May 2023 | |||
Not Applicable | - | 750 | wefyxkfwyk(pudttsumrp) = ydpivatiar yxewniwhfx (fywocrfusu ) | Positive | 08 May 2020 | ||
wefyxkfwyk(pudttsumrp) = jfgjsohnbe yxewniwhfx (fywocrfusu ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free